NT NTLA Intellia Therapeutics, Inc Loading... : Bullish and Bearish Analyst Opinions

The author notes that most gene therapies like NTLA's wear off quickly, implying a skeptical view of durability without an explicit short call.

The author questions why NTLA hasn't fallen below its offering price despite being poorly funded, implying bearish surprise but without an explicit forward-looking trade call.

Bearish view on NTLA as the filing reveals ongoing ODT demand, undercutting the need for NTLA's gene-editing therapy meant to replace ODT.

Bearish view on NTLA as the opening short-covering rally fades; biotech weakness (XBI -2%) and heavy early volume exhaustion point to a reversal lower by close.

Adam May sarcastically claims to be the largest holder of NTLA while criticizing Cathie Wood's ARK fund performance and management fees.

Adam May mocks Tony for criticizing SGMO's decline while NTLA has been a disaster, comparing the behavior to prison psychology and referencing Tony's criminal record.

Short NTLA due to insufficient cash raise ($150M vs $500M needed) and high burn rate (~$100M/Q), forcing further dilution or debt that will drive share price lower.

Dirk Haussecker warns that shorts in NTLA will be desperate to participate in a potential offering, urging Intellia to avoid rewarding them.

Buy NTLA as the speaker expects the stock to rise above its offering price, implying a catalyst from the offering itself.

NTLA is raising $150M through a secondary offering at approximately a 20% discount, a dilutive capital event.

Bearish view on NTLA due to severe undercapitalization: only raised $150M at a 20% discount against $500M needed, with $100M/Q burn rate, forcing further dilution or debt raises.

Bearish view on NTLA because existing HAE treatments already achieve higher attack-free rates in real-world settings than NTLA's OLE data suggests, and the platform's liver toxicity risk is not justified.

Notes the stock price decline exceeds a clinical metric (attack rate reduction), but does not commit to a directional trade.

Existing HAE treatments already deliver high attack-free rates in real-world practice, making NTLA's experimental therapy unnecessary and its platform's liver toxicity risk unacceptable.

Short/avoid ORKA, APGE, and NTLA; bullish survey data is flawed because it ignores generic competition that will erode the advantage of sparser dosing.

Bearish view on NTLA as chronic disease drugs going generic will provide cheaper alternatives, undermining its expensive gene therapy.

Bearish view on NTLA due to inadequate capital raise, weak HAE data, strong competition and biosimilar threat, plus ATTR study delays and unresolved safety signal (Hy's law).

Short $NTLA based on a dilution spiral thesis: the company urgently needs financing, so falling share prices worsen implied dilution, creating a self-reinforcing downside loop.

Bearish view on NTLA because clinical trial data disappointed relative to bullish expectations, likely worsened by the open-label design inflating prior efficacy readings.

Adam May questions how NTLA will raise cash after its stock finally turned red, suggesting forced debt could pressure the stock further.

Adam May boasts a strong short-selling track record with past wins on NTLA, HIMS, VKTX, and IOVA, and expresses a forward-looking bearish view on ORKA.

Adam May quotes Bio Stocks reporting NTLA's ATM offering increase from $750M to $1.04B, with $635M already raised, indicating ongoing dilution pressure.

Bearish view on $NTLA due to severe capital constraints, dilutive ATM dependence, underwhelming HAE launch prospects against strong competitors and looming biosimilar, plus delayed ATTR studies with major safety signals.

Adam May reassures a fellow trader that NTLA's stock price is unchanged from Friday's close, implying no urgent move despite prior volatility.

Adam May replies to Sanctuary Bio with a devil emoji and ticker $NTLA, but provides no explicit directional view or analysis.

Bearish view on NTLA after poor clinical data (62% attack free rate missed bar) makes fundraising difficult and ATTR studies stalled, pressuring shares.

NTLA's 87% attack reduction but only 62% attack free rate missed the pre-set bar, leading the author to express worse-than-expected disappointment and a negative view on the stock.

Despite expecting strong upcoming efficacy data, commercial viability is highly doubtful due to severe safety risks and the availability of safer, traditional treatments.

The author expresses strong confidence in upcoming clinical data for NTLA, anticipating positive efficacy and safety results that could serve as a significant catalyst for the stock.

In the outro, Becky Quick teases the next episode featuring a child who received a "personalized CRISPR-based gene editing therapy" that likely saved his life. While a teaser, this highlights the shift of CRISPR technology from theoretical research to applied clinical success ("miracles"). Positive real-world outcomes in rare diseases validate the platforms of major gene-editing companies, justifying premium valuations for their pipelines. Long the CRISPR innovators as clinical validation accelerates. Regulatory hurdles; high cost of personalized therapies limiting total addressable market (TAM).